Fei Liu1, Qin Hu1, Bo Li1, Anatol Manaenko1, Yujie Chen1, Junjia Tang1, Zongduo Guo1, Jiping Tang1, John H Zhang2. 1. From the Department of Physiology and Pharmacology (F.L., Q.H., B.L., A.M., Y.C., Junjia Tang, Z.G., Jiping Tang, J.H.Z.) and Department of Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, Loma Linda, CA; and Department of Neurosurgery, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China (F.L.). 2. From the Department of Physiology and Pharmacology (F.L., Q.H., B.L., A.M., Y.C., Junjia Tang, Z.G., Jiping Tang, J.H.Z.) and Department of Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, Loma Linda, CA; and Department of Neurosurgery, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China (F.L.). johnzhang3910@yahoo.com.
Abstract
BACKGROUND AND PURPOSE: Milk fat globule-EGF factor-8 (MFGE8) has been reported to be neuroprotective in ischemic stroke. However, the effects of MFGE8 in early brain injury after subarachnoid hemorrhage (SAH) have not been investigated. We investigated the role of MFGE8 in early brain injury and the potential mechanisms in antioxidation after SAH. METHODS: Two dosages (1 μg and 3.3 μg) of recombinant human MFGE8 were injected intracerebroventricularly at 1.5 hours after SAH. SAH grades, neurological scores, and brain water content were measured at 24 and 72 hours. For mechanistic study, MFGE8 siRNA, integrin β3 siRNA, and heme oxygenase (HO) inhibitor SnPP IX were used for intervention. The oxidative stress and expression of MFGE8, integrin β3, HO-1, extracellular signal-regulated kinase, and nuclear factor erythroid 2-related factor 2 were measured by Western blots 24 hours after SAH. RESULTS: The expression of MFGE8 and HO-1 increased and peaked 24 hours after SAH. Administration of recombinant human MFGE8 decreased brain water content and improved neurological functions both at 24 hours and at 72 hours after SAH. Recombinant human MFGE8 reduced oxidative stress and enhanced the expression of extracellular signal-regulated kinase, nuclear factor erythroid 2-related factor 2, and HO-1; and the effects were abolished by integrin β3 siRNA and HO inhibitor SnPP IX. CONCLUSIONS: Recombinant MFGE8 attenuated oxidative stress that may be mediated by integrin β3/nuclear factor erythroid 2-related factor 2/HO pathway after SAH. Recombinant MFGE8 may serve as an alternative treatment to ameliorate early brain injury for SAH patients.
BACKGROUND AND PURPOSE:Milk fat globule-EGF factor-8 (MFGE8) has been reported to be neuroprotective in ischemic stroke. However, the effects of MFGE8 in early brain injury after subarachnoid hemorrhage (SAH) have not been investigated. We investigated the role of MFGE8 in early brain injury and the potential mechanisms in antioxidation after SAH. METHODS: Two dosages (1 μg and 3.3 μg) of recombinant humanMFGE8 were injected intracerebroventricularly at 1.5 hours after SAH. SAH grades, neurological scores, and brain water content were measured at 24 and 72 hours. For mechanistic study, MFGE8 siRNA, integrin β3 siRNA, and heme oxygenase (HO) inhibitor SnPP IX were used for intervention. The oxidative stress and expression of MFGE8, integrin β3, HO-1, extracellular signal-regulated kinase, and nuclear factor erythroid 2-related factor 2 were measured by Western blots 24 hours after SAH. RESULTS: The expression of MFGE8 and HO-1 increased and peaked 24 hours after SAH. Administration of recombinant humanMFGE8 decreased brain water content and improved neurological functions both at 24 hours and at 72 hours after SAH. Recombinant humanMFGE8 reduced oxidative stress and enhanced the expression of extracellular signal-regulated kinase, nuclear factor erythroid 2-related factor 2, and HO-1; and the effects were abolished by integrin β3 siRNA and HO inhibitor SnPP IX. CONCLUSIONS: Recombinant MFGE8 attenuated oxidative stress that may be mediated by integrin β3/nuclear factor erythroid 2-related factor 2/HO pathway after SAH. Recombinant MFGE8 may serve as an alternative treatment to ameliorate early brain injury for SAHpatients.
Authors: Mingyi Wang; Zongming Fu; James Wu; Jing Zhang; Liqun Jiang; Benjamin Khazan; Richard Telljohann; Mingming Zhao; Alexander W Krug; Maria Pikilidou; Robert E Monticone; Robert Wersto; Jennifer Van Eyk; Edward G Lakatta Journal: Aging Cell Date: 2012-04-04 Impact factor: 9.304
Authors: T Satoh; S-i Okamoto; J Cui; Y Watanabe; K Furuta; M Suzuki; K Tohyama; S A Lipton Journal: Proc Natl Acad Sci U S A Date: 2006-01-09 Impact factor: 11.205
Authors: Julian Cahill; W Julian Cahill; John W Calvert; John H Calvert; John H Zhang Journal: J Cereb Blood Flow Metab Date: 2006-02-15 Impact factor: 6.200
Authors: Jiang Wu; Yang Zhang; Peng Yang; Budbazar Enkhjargal; Anatol Manaenko; Jiping Tang; William J Pearce; Richard Hartman; Andre Obenaus; Gang Chen; John H Zhang Journal: Stroke Date: 2016-03-22 Impact factor: 7.914